Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Head & Face Medicine
Published in: Head & Face Medicine 1/2011

Open Access 01-12-2011 | Case report

Autologous bone marrow stem cell intralesional transplantation repairing bisphosphonate related osteonecrosis of the jaw

Authors: Luigi Cella, Aldo Oppici, Mariacristina Arbasi, Mauro Moretto, Massimo Piepoli, Daniele Vallisa, Adriano Zangrandi, Camilla Di Nunzio, Luigi Cavanna

Published in: Head & Face Medicine | Issue 1/2011

Login to get access

Abstract

Purpose

Bisphosphonate - related osteonecrosis of the JAW (BRONJ) is a well known side effect of bisphosphonate therapies in oncologic and non oncologic patients. Since to date no definitive consensus has been reached on the treatment of BRONJ, novel strategies for the prevention, risk reduction and treatment need to be developed. We report a 75 year old woman with stage 3 BRONJ secondary to alendronate and pamidronate treatment of osteoporosis. The patient was unresponsive to recommended treatment of the disease, and her BRONJ was worsening. Since bone marrow stem cells are know as being multipotent and exhibit the potential for differentiation into different cells/tissue lineages, including cartilage, bone and other tissue, we performed autologous bone marrow stem cell transplantation into the BRONJ lesion of the patient.

Methods

Under local anesthesia a volume of 75 ml of bone marrow were harvested from the posterior superior iliac crest by aspiration into heparinized siringes. The cell suspension was concentrated, using Ficoll - Hypaque® centrifugation procedures, in a final volume of 6 ml. Before the injection of stem cells into the osteonecrosis, the patient underwent surgical toilet, local anesthesia was done and spongostan was applied as a carrier of stem cells suspension in the bone cavity, then 4 ml of stem cells suspension and 1 ml of patient's activated platelet-rich plasma were injected in the lesion of BRONJ.

Results

A week later the residual spongostan was removed and two weeks later resolution of symptoms was obtained. Then the lesion improved with progressive superficialization of the mucosal layer and CT scan, performed 15 months later, shows improvement also of bone via concentric ossification: so complete healing of BRONJ (stage 0) was obtained in our patient, and 30 months later the patient is well and without signs of BRONJ.

Conclusion

To our knowledge this is the first case of BRONJ successfully treated with autologous stem cells transplantation with a complete response.
Appendix
Available only for authorised users
Literature
1.
McClug MR: Bisphosphonates. Endocrinol Metab Clin North Am. 2003, 32: 253 71
2.
Santini D, Vespasiani Gentilucci U, Vincenzi B, Picardi A, Vasaturo F: The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol. 2003, 14: 1468-76. 10.1093/annonc/mdg401.CrossRefPubMed
3.
Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD: Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. 1997, 57: 3890-3894.PubMed
4.
Wysoski DK: Reports of esophageal cancer with oral bisphosphonates use. N Engl J Med. 2009, 360: 89-90. 10.1056/NEJMc0808738.CrossRef
5.
Ibrahim T, Barbanti F, Giorgio Marrano G, Mercatali L, Ronconi S, Vicini C: Osteonecrosis of the Jaw in patients with bone matastases treated with bisphosphonates: a retrospective study. Oncologist. 2008, 13: 330-336. 10.1634/theoncologist.2007-0159.CrossRefPubMed
6.
Bagan JV, Jimenez Y, Murillo J, Hernandez S, Poveda R, Sanchis JM: Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral oncol. 2006, 42: 327-329. 10.1016/j.oraloncology.2005.08.001.CrossRefPubMed
7.
Hewitt C, Farah C: Bisphosphonates-related osteonecrosis of the jaws: a comprehensive review. J Oral Pathol Med. 2007, 36: 319-328. 10.1111/j.1600-0714.2007.00540.x.CrossRefPubMed
8.
American Dental Association Council on Scientific Affairs: Dental Management of patients receiving oral bisphosphonate Therapy: Expert panel recommendations. J Am Assoc. 2006, 137: 1144-1150.
9.
Cavanna L, Bertè R, Arcari A, Mordenti P, Pagani R, Vallisa D: Osteonecrosis of the Jaw. A newly emerging sete-specific osseous pathology in opatients with cancer treated with bisphosphonates. Report of 5 cases and review of the literature. Eur J Internal Med. 2007, 18: 417-422. 10.1016/j.ejim.2006.10.008.CrossRef
10.
Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D: Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone. 2008, 42: 841-847. 10.1016/j.bone.2008.01.003.CrossRefPubMed
11.
Marx RE, Sawatari Y, Fortin M, Broumand V: Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg. 2005, 63: 1567-1575. 10.1016/j.joms.2005.07.010.CrossRefPubMed
12.
Yarom N, Yahalom R, Shoshani Y, Hamed W, Regev E, Elad S: Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and teatment outcome. Osteoporos Int. 2007, 18: 1363-1370. 10.1007/s00198-007-0384-2.CrossRefPubMed
13.
Elad S, Yarom N, Hamed W, Ayalon S, Yahalom R, Regev E: Osteomyelitis and necrosis of the jaw in patients treated with bisphosphonates A comparative study. Clin Lab Haematol. 2006, 28: 393-398. 10.1111/j.1365-2257.2006.00841.x.CrossRefPubMed
14.
Ruggiero SL, Fantasia J, Carlson E: Bisphosphonates-related osteonecrosis of the jaw: background and guidlines for diagnosis, staging and management. Oral Surg. Oral Med Oral Path Oral Radio Endod. 2006, 102: 433-41. 10.1016/j.tripleo.2006.06.004.CrossRef
15.
Vescovi P, Merigo E, Meleti M, Fornaini C, Bonanini M, Rocca EP, De Moor RJ, Nammour S: Surgical treatment of maxillary osteonecrosis due to bisphosphonates using an Er: YAG (2940 nm) laser. Discussion of 17 clinical cases. Rev Belge Med Dent. 2009, 64 (2): 87-95.
16.
Rugani P, Stephan A, Truschnegg A, Obermayer-Pietsch B, Jakse N: Bisphosphonate - associated osteonecrosis of the jaws: surgical treatment with ErCrYSGG-laser. Case report. OOOOE. 2010, 110: e1-e6.PubMed
17.
Ruggiero SL, Dodson TB, Assale LA, Landesberg R, Marx RE, Mehrotra B: American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Relate Osteonecrosis of the Jaws-2009 Update. J Oral Maxillofac Surg. 2009, 67 (Suppl): 2-12.PubMed
18.
Madrid C, Bouferrache K, Abarca M, Jaques B, Broome M: Bisphosphonate-related osteonecrosis of the jaws: how to manage cancer patients. Oral Oncology. 2010, 46: 468-470. 10.1016/j.oraloncology.2010.03.016.CrossRefPubMed
19.
Lee JJ, Cheng SJ, Jeng JH, Ching CP, Lau HP, Kok SH: Successful treatment of advanced bisphosphonate-related osteonecrosis of the mandible with adjunctive teriparatide therapy. Wiley InterScience. 2010, [http://​www.​interscience.​wiley.​com]
20.
Wilde F, Heufelder M, Winter K, Hendricks J, Frerich B, Schramm A, Hemprich A: The role of surgical therapy in the management of intravenous bisphosphonates-related osteonecrosis of the jaw. OOOOE. 2010
21.
Korbling M, Estrov Z: Adult stem cells for tissue repair--a new therapeutic concept?. N Engl J Med. 2003, 349: 570-582. 10.1056/NEJMra022361.CrossRefPubMed
22.
Schneuder RK, Puellen A, Kramann R, Raupach K, Bornemann J, Knuechel R, Perez-Buoza A, Neuss S: The osteogenic differentiation of adult bone marrow and perinatal umbilical mesenchymal stem cells and matrix remodelling in three-dimensional collagen scaffolds. Biomaterial. 2010, 31: 467-480. 10.1016/j.biomaterials.2009.09.059.CrossRef
23.
Ruggiero S, Gralow J, Marx RE, Hoff AO, Schubert MM, Huryn JM, Toth B, Damato K, Valero V: Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Prac. 2006, 2: 7-14. 10.1200/JOP.2.1.7.CrossRef
24.
Gussoni E, Soneoka Y, Strickland CD, Buzney EA, Khan MK, Flint AF, Kunkel LM, Mulligan RC: Dystrophin expression in the mdx mouse restored by stem cell transplantation. Nature. 1999, 401: 309-394.
25.
Petersen BE, Bowen WC, Patrene KD, Mars WM, Sullivan AK, Murase N, Boggs SS, Greenberger JS, Goff JP: Bone marrow as a potential source of hepatic oval cells. Science. 1999, 284: 1168-1170. 10.1126/science.284.5417.1168.CrossRefPubMed
26.
Piepoli M, Vallisa D, Arbasi C, Cavanna L, Cerri L, Mori M, Passerini F, Tommasi L, Rossi A, Capuccci A: Bone marrow cell transplantation improves cardiac, autonomic, and functional indexes in acute anterior myocardial infarction patients (Cardiac Study). European Journal of Heart Failure.
27.
Marx RE: Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaw: a growing epidemic. J Oral Maxillofac Surg. 2003, 61: 1115-1117. 10.1016/S0278-2391(03)00720-1.CrossRefPubMed
28.
Wang J, Goodger NM, Pogrel MA: Osteonecrosis of the jawsmassociated with cancer chemotherapy. J Oral Maxillofac Surg. 2003, 61: 1104-1107. 10.1016/S0278-2391(03)00328-8.CrossRefPubMed
29.
Edwards BJ, Gounder M, McKoy JM, Boyd I, Farrugia M, Migliorati C, Marx R, Ruggiaero S, Dimopoulos M, Raisch DW, Singhal S, Carson K, Obadina E, Trifilio S, West D, Mehta J, Bennett CL: Bisphosphonate use and osteonecrosis of the jaw: Pharmacovigilance and reporting of this serious adverse event. Lancet Oncol. 2008, 9: 1166-10.1016/S1470-2045(08)70305-X.CrossRefPubMed
30.
Salamon A, Toldy E: Use of mesenchymal stem cells from adult bone marrow for injured tissue repair. Orv Hetil. 2009, 150 (27): 1259-1265. 10.1556/OH.2009.28666.CrossRefPubMed
31.
Connolly J, Grese R, Lipello L, Dehne R: Development of an osteogenic bone marrow preparation. J Bone Joint Surg. 1989, 71A: 684-691.
32.
Muschler G, Boehm C, Easley K: Aspiration to obtain osteoblast progenitor cells from human bone marrow: the influence of aspiration volume. J Bone Joint Surg. 1997, 79A: 1699-1707.
33.
Usami K, Mizuno H, Okada K, Narita Y, Aoki M, Kondo T, Mizuno D, Mase J, Nishiguchi H, Kagami H, Minoru U: Composite implantation of mesenchymal stem cells with endothelial progenitor cells enhances tissue-engineered bone formation. J Biomed Mater Res A. 2009, 90 (3): 730-41.CrossRefPubMed
34.
Bittira B, Shum-Tim D, Al-Khaldi A, Chiu RC: Mobilization and homing of bone marrow stromal cells in Myocardial infarction. Eur J Cardiotoracic Surg. 2003, 24: 393-398. 10.1016/S1010-7940(03)00325-7.CrossRef
35.
Prockop DJ: Marrow stromal cells as stem cells for nonhematopoietic tissues. Science. 1997, 276: 71-74. 10.1126/science.276.5309.71.CrossRefPubMed
36.
Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, Inai Y, Silver M, Isner JM: VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999, 18: 3964-3972. 10.1093/emboj/18.14.3964.CrossRefPubMedPubMedCentral
37.
Orlic D, Kajstura J, Chimenti S, Bodine DM, Leri A, Anversa P: Bone marrow cells regenerate infracted myocardium. Nature. 2001, 410: 701-705. 10.1038/35070587.CrossRefPubMed
38.
Smart N, Riley PR: The stem cell movement. Circ Res. 2008, 102: 1155 1168
39.
Sun J, Li SH, Liu SM, Wu J, Weisel RD, Zhuo YF, Yau TM, Li Rk, Fazel SS: Improvement in cardiac function after bone marrow cell therapy is associated with an increase in myocardial inflammation. Am J Physiol Heart Circ Physiol. 2009, 296: H43-H50.CrossRefPubMed
40.
Kikuiri T, Kin I, Yamaza T, Akiyama K, Zhang Q, Li Y, Chen C, Chen C, Wang S, le AD, Shi S: Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw - like disease in mice. J Bone Miner Res. 2010, 25 (7): 1668-79. 10.1002/jbmr.37.CrossRefPubMedPubMedCentral
41.
Handschel J, Meyer U: Infection, vascularization, remodelling - are stem cell the answers for bone disease of the jaw?. Head & Face Medicine. 2011, 7: 5-10.1186/1746-160X-7-5.CrossRef
Metadata
Title
Autologous bone marrow stem cell intralesional transplantation repairing bisphosphonate related osteonecrosis of the jaw
Authors
Luigi Cella
Aldo Oppici
Mariacristina Arbasi
Mauro Moretto
Massimo Piepoli
Daniele Vallisa
Adriano Zangrandi
Camilla Di Nunzio
Luigi Cavanna
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Head & Face Medicine / Issue 1/2011
Electronic ISSN: 1746-160X
DOI
https://doi.org/10.1186/1746-160X-7-16

Other articles of this Issue 1/2011

Head & Face Medicine 1/2011 Go to the issue

Research

Increase in periosteal angiogenesis through heat shock conditioning

Methodology

Reconstruction of defects of maxillary sinus wall after removal of a huge odontogenic lesion using prebended 3D titanium-mesh and CAD/CAM technique

Research

In vitro analysis of the cytotoxicity and the antimicrobial effect of four endodontic sealers

Review

Evaluation of the mechanism and principles of management of temporomandibular joint dislocation. Systematic review of literature and a proposed new classification of temporomandibular joint dislocation

Methodology

Piezoelectric-assisted removal of a benign fibrous histiocytoma of the mandible: An innovative technique for prevention of dentoalveolar nerve injury

Research

Embryonic stem cells in scaffold-free three-dimensional cell culture: osteogenic differentiation and bone generation